Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.62 |
| ▸ | TBXAS1 | P24557 | 17/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23844568 | 0.90 | TBXAS1 (0.57) | EGLN3TBXAS1 | |
| SCHEMBL47372 | 0.88 | EGLN3 (0.61) | EGLN3TBXAS1ALDH1A1 | |
| SCHEMBL12391736 | 0.83 | ALDH1A1 (0.62) | EGLN3TBXAS1ALDH1A1 | |
| SCHEMBL4288379 | 0.79 | EGLN3 (0.69) | EGLN3TBXAS1ALDH1A1 | |
| SCHEMBL14087955 | 0.79 | TBXAS1 (0.48) | EGLN3TBXAS1ALDH1A1 | |
| SCHEMBL21661627 | 0.78 | EGLN3 (0.57) | EGLN3TBXAS1ALDH1A1 | |
| SCHEMBL22490369 | 0.78 | EGLN3 (0.57) | EGLN3TBXAS1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL3642733 | 0.78 | EGLN3 (0.67) | EGLN3TBXAS1ALDH1A1 | |
| SCHEMBL2001103 | 0.77 | EGLN3 (1.00) | EGLN3TBXAS1ALDH1A1 | |
| SCHEMBL10780853 | 0.76 | EGLN3 (0.65) | EGLN3TBXAS1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | SHY Therapeutics LLC (US) | 2023-05-18 | — | — | US | disclosed |
| US-11213515-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2022-01-04 | — | — | US | disclosed |
| US-5789432-A | Aromatase-inhibiting composition containing azole derivative | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1998-08-04 | — | — | US | disclosed |
| US-5726196-A | TREATING BREAST CANCER, BENIGN BREAST DISEASE, UTERINE CANCER, PANCREATIC CRCINOMA, CUSHING'S SYNDROME | NIIMURA KOICHI (JP) | 1998-03-10 | — | — | US | disclosed |
| EP-0654265-A1 | Aromatase-inhibiting composition containing azole derivative | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1995-05-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11213515-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | EGLN3 2796/4885TBXAS1 1065/4885ALDH1A1 3448/4885 |
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | HRAS, KRAS, NRAS | EGLN3 2796/4885TBXAS1 1065/4885ALDH1A1 3448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.